Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action
- PMID: 807550
- DOI: 10.7164/antibiotics.28.543
Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action
Abstract
In vivo, at low concentrations (less than or equal to 1 mug/ml), the antibiotic lipiarmycin specifically inhibits RNA synthesis in Bacillus subtilis. At a much higher concentration (100 mug/ml), syntheses of other macromolecules such as DNA and protein also appear to be suppressed. In vitro, the antibiotic caused 50% inhibition of DNA-dependent RNA-polymerase from B. subtilis at a concentration of 0.6 mug/ml and of that E. coli at 5 approximately 8 mug/ml. The activity of Escherichia coli DNA-polymerase I is inhibited 50% at 55 approximately 65 mug/ml. Lipiarmycin prevent ribonucleoside triphosphate polymerization only if added prior to the association between RNA-polymerase and DNA, and does not affect the elongation rate of RNA chains at concentrations up to 100 mug/ml. At that concentration, however, the antibiotic immediately blocks the polymerization of deoxyribonucleotide triphosphates catalyzed by DNA-polymerase I.
Similar articles
-
Lipiarmycin: an antibiotic inhibiting nucleic acid polymerases.Biochem Biophys Res Commun. 1975 Mar 3;63(1):328-34. doi: 10.1016/s0006-291x(75)80047-7. Biochem Biophys Res Commun. 1975. PMID: 1092299 No abstract available.
-
Effects of the antibiotic resistomycin on the synthesis of macromolecules.Z Allg Mikrobiol. 1975;15(6):411-21. doi: 10.1002/jobm.3630150604. Z Allg Mikrobiol. 1975. PMID: 812270
-
On the mode of action of ASK-753, a new iron-containing antibiotic.J Antibiot (Tokyo). 1974 Nov;27(11):874-83. doi: 10.7164/antibiotics.27.874. J Antibiot (Tokyo). 1974. PMID: 4217791 No abstract available.
-
Lipiarmycin-resistant ribonucleic acid polymerase mutants of Bacillus subtilis.J Bacteriol. 1977 Oct;132(1):73-9. doi: 10.1128/jb.132.1.73-79.1977. J Bacteriol. 1977. PMID: 410787 Free PMC article.
-
New target for inhibition of bacterial RNA polymerase: 'switch region'.Curr Opin Microbiol. 2011 Oct;14(5):532-43. doi: 10.1016/j.mib.2011.07.030. Epub 2011 Aug 19. Curr Opin Microbiol. 2011. PMID: 21862392 Free PMC article. Review.
Cited by
-
Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.Infect Drug Resist. 2013 Jun 28;6:41-53. doi: 10.2147/IDR.S24434. Print 2013. Infect Drug Resist. 2013. PMID: 23843696 Free PMC article.
-
New antimicrobial agents for patients with Clostridium difficile infections.Curr Infect Dis Rep. 2009 Jan;11(1):21-8. doi: 10.1007/s11908-009-0004-8. Curr Infect Dis Rep. 2009. PMID: 19094821
-
Natural Products as Platforms To Overcome Antibiotic Resistance.Chem Rev. 2017 Oct 11;117(19):12415-12474. doi: 10.1021/acs.chemrev.7b00283. Epub 2017 Sep 27. Chem Rev. 2017. PMID: 28953368 Free PMC article. Review.
-
Transcription inhibition by the depsipeptide antibiotic salinamide A.Elife. 2014 Apr 30;3:e02451. doi: 10.7554/eLife.02451. Elife. 2014. PMID: 24843001 Free PMC article.
-
Antibacterial Nucleoside-Analog Inhibitor of Bacterial RNA Polymerase.Cell. 2017 Jun 15;169(7):1240-1248.e23. doi: 10.1016/j.cell.2017.05.042. Cell. 2017. PMID: 28622509 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources